Epidemiology of and Factors Associated with Overall Survival for Patients with Head and Neck Adenoid Cystic Carcinoma

Overview

Journal J Cancer Res Clin Oncol

Specialty Oncology

Date 2023 Aug 7

PMID 37548774

Authors

DongJie He

Siying Zhu

Qianqian Zhao

Hao Chang

Gaiyan Li

Qiuju Shao

Chao Zhang

Peiwen Wu

Affiliations

Soon will be listed here.

Abstract

Background: Updated epidemiologic and survival data of head and neck adenoid cystic carcinoma (HNACC) are lacking. This retrospective study aimed to clarify the incidence, prevalence, and overall survival (OS) of patients with HNACC and establish relevant nomogram.

Methods: Trends in incidence, limited-duration prevalence, and relative survival (RS) rates were evaluated using data from the Surveillance, Epidemiology, and End Results (SEER) database, and annual percent change (APC) in rates was calculated using joinpoint regression. Data on age, sex, site, stage, and surgery were used in construction and validation of the nomogram.

Results: The study included 6474 patients; 57.7% were female and 78.6% were white. The age-adjusted incidence rates of HNACC decreased significantly from 0.41 to 0.25 per 100,000 [1975-2018; average annual percent change (AAPC): - 1.37, P < 0.001], which was dominated by the localized stage. The 20-year limited duration prevalence increased from 0.00028% to 0.00262%. The 5- and 10-year RS rates of all HNACC patients were 80.0% and 65.5%, respectively. RS rates in HNACC showed a slight increase over time, with APC values of 0.03 for 5-year (P < 0.05) and 0.13 for 10-year (P < 0.05) RS. A prognostic model was constructed. The C-indices for the training and testing sets were both 0.734. The nomogram's discrimination efficiency was evaluated using the receiver operating characteristic curve and had moderate predictive power.

Conclusions: Over the past 40 years, the incidence of HNACC decreased accompanied by slightly improved survival rates. Nomogram was capable of predicting the 5- and 10-year OS rates with moderate accuracy.

Citing Articles

PSMA-Guided Imaging and Therapy of Advanced Adenoid Cystic Carcinomas and Other Salivary Gland Carcinomas.

Trautwein N, Brendlin A, Reischl G, Mattke M, Paulsen F, Loewenheim H Cancers (Basel). 2024; 16(22).

PMID: 39594798 PMC: 11592976. DOI: 10.3390/cancers16223843.

Molecular Aspects of Mucoepidermoid Carcinoma and Adenoid Cystic Carcinoma of the Salivary Gland.

Costa R, de Oliveira C, Gomes A, Lourenco S, Coutinho-Camillo C Head Neck Pathol. 2024; 18(1):34.

PMID: 38658430 PMC: 11043314. DOI: 10.1007/s12105-024-01629-2.

References

An L, Ju W, Zheng R, Zeng H, Zhang S, Chen R . Trends in survival for cancer patients aged 65 years or over from 1995 to 2014 in the United States: A population-based study. Cancer Med. 2022; 12(5):6283-6293. PMC: 10028112. DOI: 10.1002/cam4.5398. View

Atallah S, Casiraghi O, Fakhry N, Wassef M, Uro-Coste E, Espitalier F . A prospective multicentre REFCOR study of 470 cases of head and neck Adenoid cystic carcinoma: epidemiology and prognostic factors. Eur J Cancer. 2020; 130:241-249. DOI: 10.1016/j.ejca.2020.01.023. View

Behbahani S, Wassef D, Povolotskiy R, Pinto J, Joseph N, Paskhover B . Analysis of Characteristics and Survival of Primary Cutaneous Adenoid Cystic Carcinoma of the Head and Neck. Ann Otol Rhinol Laryngol. 2020; 130(1):12-17. DOI: 10.1177/0003489420936719. View

Bonaparte J, Hart R, Trites J, Taylor M . Incidence of adenoid cystic carcinoma in nova scotia: 30-year population-based epidemiologic study. J Otolaryngol Head Neck Surg. 2009; 37(5):642-8. View

Cai H, Huang S, Liang J, Zhu Y, Hou J . Clinical Prediction Nomograms to Assess Overall Survival and Disease-Specific Survival of Patients with Salivary Gland Adenoid Cystic Carcinoma. Biomed Res Int. 2022; 2022:7894523. PMC: 9444442. DOI: 10.1155/2022/7894523. View

Cavalieri S, Mariani L, Vander Poorten V, Van Breda L, Cau M, Lo Vullo S . Prognostic nomogram in patients with metastatic adenoid cystic carcinoma of the salivary glands. Eur J Cancer. 2020; 136:35-42. DOI: 10.1016/j.ejca.2020.05.013. View

Chen M, He X, Yang Q, Zhang J, Peng J, Wang D . Epidemiology and prediction model of patients with carcinosarcoma in the United States. Front Public Health. 2022; 10:1038211. PMC: 9742429. DOI: 10.3389/fpubh.2022.1038211. View

Choi S, Yang A, Yoon S, Kim H, Hong M, Kim S . Role of postoperative radiotherapy in resected adenoid cystic carcinoma of the head and neck. Radiat Oncol. 2022; 17(1):197. PMC: 9716721. DOI: 10.1186/s13014-022-02165-5. View

Coca-Pelaz A, Rodrigo J, Bradley P, Vander Poorten V, Triantafyllou A, Hunt J . Adenoid cystic carcinoma of the head and neck--An update. Oral Oncol. 2015; 51(7):652-61. DOI: 10.1016/j.oraloncology.2015.04.005. View

10.

Perez D, de Abreu Alves F, Nishimoto I, de Almeida O, Kowalski L . Prognostic factors in head and neck adenoid cystic carcinoma. Oral Oncol. 2005; 42(2):139-46. DOI: 10.1016/j.oraloncology.2005.06.024. View

11.

Dai L, Zhang S, Wu Y . Prognostic Model and Nomogram for Early-Onset Adenoid Cystic Carcinoma of Head and Neck: A Retrospective SEER-Based Analysis. Technol Cancer Res Treat. 2023; 22:15330338231163026. PMC: 10126692. DOI: 10.1177/15330338231163026. View

12.

Dasari A, Shen C, Halperin D, Zhao B, Zhou S, Xu Y . Trends in the Incidence, Prevalence, and Survival Outcomes in Patients With Neuroendocrine Tumors in the United States. JAMA Oncol. 2017; 3(10):1335-1342. PMC: 5824320. DOI: 10.1001/jamaoncol.2017.0589. View

13.

Del Signore A, Megwalu U . The rising incidence of major salivary gland cancer in the United States. Ear Nose Throat J. 2017; 96(3):E13-E16. DOI: 10.1177/014556131709600319. View

14.

Dewenter I, Otto S, Kakoschke T, Smolka W, Obermeier K . Recent Advances, Systemic Therapy, and Molecular Targets in Adenoid Cystic Carcinoma of the Head and Neck. J Clin Med. 2023; 12(4). PMC: 9967509. DOI: 10.3390/jcm12041463. View

15.

Dodd R, Slevin N . Salivary gland adenoid cystic carcinoma: a review of chemotherapy and molecular therapies. Oral Oncol. 2006; 42(8):759-69. DOI: 10.1016/j.oraloncology.2006.01.001. View

16.

Dubal P, Unsal A, Chung S, Patel A, Park R, Baredes S . Population-based trends in outcomes in adenoid cystic carcinoma of the oral cavity. Am J Otolaryngol. 2016; 37(5):398-406. DOI: 10.1016/j.amjoto.2016.06.001. View

17.

Fang Y, Peng Z, Wang Y, Gao K, Liu Y, Fan R . Current opinions on diagnosis and treatment of adenoid cystic carcinoma. Oral Oncol. 2022; 130:105945. DOI: 10.1016/j.oraloncology.2022.105945. View

18.

Gatta G, Guzzo M, Locati L, McGurk M, Prott F . Major and minor salivary gland tumours. Crit Rev Oncol Hematol. 2020; 152:102959. DOI: 10.1016/j.critrevonc.2020.102959. View

19.

Gupta A, Koochakzadeh S, Neskey D, Nguyen S, Lentsch E . Incidence and survival trends of parotid malignancies over 42 years. Head Neck. 2020; 42(9):2308-2315. DOI: 10.1002/hed.26172. View

20.

Ishida E, Ogawa T, Rokugo M, Ishikawa T, Wakamori S, Ohkoshi A . Management of adenoid cystic carcinoma of the head and neck: a single-institute study with over 25-year follow-up. Head Face Med. 2020; 16(1):14. PMC: 7330995. DOI: 10.1186/s13005-020-00226-2. View